As of March 31, 2025, CMPX reported cash and marketable securities totaling $113 million, a decrease from $127 million recorded on December 31, 2024. This provides the company with a projected financial runway extending through 2027. Over the initial quarter of 2025, CMPX utilized $13 million in net cash for its operational activities.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Compass Therapeutics Inc (CMPX, Financial) is $13.10 with a high estimate of $32.00 and a low estimate of $6.00. The average target implies an upside of 644.32% from the current price of $1.76. More detailed estimate data can be found on the Compass Therapeutics Inc (CMPX) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Compass Therapeutics Inc's (CMPX, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
